Skip to Content

Iopamidol Pregnancy and Breastfeeding Warnings

Iopamidol is also known as: Iopamidol-370, Isovue-128, Isovue-200, Isovue-250, Isovue-300, Isovue-370, Isovue-M-200, Isovue-M-300

Iopamidol Pregnancy Warnings

It is not known whether this drug crosses the placental barrier or reaches fetal tissues. However, many injectable contrast agents cross the placental barrier in humans and appear to enter fetal tissues. Intravenously administration does not induce adverse effects on fertility and general reproductive performance in rats. No teratogenic effects attributable to this drug have been observed in teratology studies performed in animals. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. There are no adequate and well controlled studies in pregnant women. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

Use is not recommended unless clearly needed. AU TGA pregnancy category: Not assigned US FDA pregnancy category: B Comments: X-ray examination of women should be conducted during the pre-ovulation phase of the menstrual cycle and should be avoided during pregnancy.

See references

Iopamidol Breastfeeding Warnings

Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: The effects in the nursing infant are unknown.

Animal experiences revealed that this drug is nontoxic in animals after oral administration. Due to the low level of absorption of this drug from the gastrointestinal tract, it is unlikely that a fetus could be exposed to significant levels. Harm to the nursing infant is unlikely to occur.

See references

References for pregnancy information

  1. "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.
  2. Zhanel GG, Mayer M, Laing N, Adam HJ "Mutant Prevention Concentrations of Levofloxacin Alone and in Combination with Azithromycin, Ceftazidime, Colistin (Polymyxin E), Meropenem, Piperacillin-Tazobactam, and Tobramycin against Pseudomonas aeruginosa." Antimicrob Agents Chemother 50 (2006): 2228-30
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.